Screener
Halozyme Therapeutics HALO Net debt / EBITDA
Net debt / EBITDA at other companies
Other financials
Where this comes from
Calculated from Halozyme Therapeutics’s reported figures.
Based on the most recent quarter.
The source filing: Halozyme Therapeutics’s 10-Q, filed November 3, 2025. Open the filing →
- Filed
- Nov 3, 2025
- Fiscal quarter
- Q3 FY2025
- Calendar quarter
- Q3 2025
- Accession
- 0001159036-25-000045
FAQ
- What is Halozyme Therapeutics's net debt / EBITDA?
- Halozyme Therapeutics (HALO) reported net debt / EBITDA of 1.5× in Q3 2025.
- How has Halozyme Therapeutics's net debt / EBITDA changed year-over-year?
- Halozyme Therapeutics's net debt / EBITDA decreased by 47.2% year-over-year, from 2.8× to 1.5×.
- What is the long-term trend for Halozyme Therapeutics's net debt / EBITDA?
- Over 4 years (2020 to 2024), Halozyme Therapeutics's net debt / EBITDA has grown at a 10.1% compound annual growth rate (CAGR), from 1.7× to 2.5×.
- What does net debt / EBITDA mean?
- Net debt (total debt minus cash) divided by trailing-twelve-month EBITDA. Expresses leverage in years — roughly how long it would take to repay net debt out of operating cash earnings.
Ask your AI about Halozyme Therapeutics's net debt / ebitda.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude